Dr. Carsten Berges

Project 1: GMP-compliant manufacturing of activated Treg for the treatment of inflammatory autoimmune diseases and GvHD Project 2: Development of cellular therapies using pharmacologically-activated Treg for the treatment of autoimmune inflammatory diseases and GvHD Project 3: Analysis of the effect of novel multiple sclerosis therapies on the responsiveness of T effector cells to the suppressive capacity of Treg

Scientist Cell Therapy Manufacturing bei BioNTech IMFS

Project 1: Development of cellular therapies using activated Treg to treat inflammatory autoimmune diseases and transplant rejection Project 2: GP120 for therapeutic activation of Treg • Design and realization of in vivo experiments using a preclinical mouse model • Design, development and implementation of in vitro and in vivo assays o Analysis of patient samples (multiple sclerosis, psoriasis, IPEX-like syndrome) • Instruction and supervision of Technical Assistants

Deputy Laboratory Manager for the Translational Immunotherapy Working Group Project 1: Identification of common signaling pathways of alloreactive T cells and primary multiple myeloma for the simultaneous treatment of GvHD and multiple myeloma (subproject in Clinical Research Group 216 "Characterization of Oncogenic Signaling Network in Multiple Myeloma: Development of Targeted Therapies") Project 2: Generation of A. fumigatus-specific Treg for adoptive T cell transfer

Phytopathologie, Mikrobiologie, Zoologie